Company Overview

Arno Therapeutics, Inc. (formerly traded under the ticker ARNI) was a clinical-stage biopharmaceutical company focused on the development of targeted therapies for cancer and other serious diseases. The company operated within the biotechnology and oncology drug development industries, with its primary activities centered on identifying, licensing, and advancing small-molecule therapeutics through clinical development. Public disclosures and historical filings indicate that Arno’s lead development programs included oncology candidates targeting hormone-resistant and treatment-resistant cancers.

The company’s principal value drivers were its investigational drug pipeline and intellectual property portfolio rather than commercial product sales, as publicly available records do not indicate sustained revenue from marketed products. Arno Therapeutics evolved through licensing arrangements and development-stage acquisitions designed to build a focused oncology pipeline. Historical company materials indicate that its strategy emphasized precision medicine approaches and partnerships with academic and research institutions. Data regarding current operating status, ongoing commercial activity, and corporate continuity is inconclusive based on available public sources.

Business Operations

Arno Therapeutics operated primarily as a development-stage biotechnology company rather than a diversified commercial pharmaceutical enterprise. Its operations were concentrated in research and development activities associated with oncology therapeutics, including preclinical studies, clinical trials, regulatory planning, and intellectual property management. The company’s historical pipeline included compounds such as onapristone extended release and other targeted cancer therapies aimed at hormone-driven malignancies. Available public filings suggest that the company relied heavily on external contract research organizations, licensing arrangements, and collaborative development structures instead of maintaining large-scale manufacturing infrastructure.

The company’s operational footprint appeared largely centered in the United States, with development and regulatory activities tied to clinical research networks and external scientific collaborators. Historical disclosures referenced relationships involving licensed compounds and research partnerships, though comprehensive details regarding active joint ventures or material international subsidiaries are limited in publicly accessible records. Data regarding current subsidiaries, active commercial partnerships, or continuing operations is inconclusive based on available public sources.

Strategic Position & Investments

Arno Therapeutics positioned itself as a specialty oncology developer focused on therapies for cancers with significant unmet medical need, particularly hormone receptor-related tumors. Its strategic direction historically emphasized advancing differentiated clinical candidates through mid-stage trials while seeking strategic partnerships, licensing opportunities, and potential commercialization arrangements with larger pharmaceutical companies. The company’s investment profile was concentrated in clinical development spending, regulatory preparation, and intellectual property protection rather than large-scale acquisitions or diversified portfolio investments.

One of the company’s notable development assets was onapristone extended release, a progesterone receptor antagonist evaluated in oncology settings. Publicly available information also indicates that Arno pursued intellectual property strategies intended to support exclusivity around formulation and therapeutic applications. However, there is limited verifiable evidence of major completed acquisitions, substantial portfolio holdings, or broad corporate investment activity comparable to larger biotechnology firms. Data regarding current strategic initiatives or active investment programs is inconclusive based on available public sources.

Geographic Footprint

Arno Therapeutics was headquartered in the United States, with historical corporate operations associated with the biotechnology corridor in New Jersey. Its activities primarily supported U.S.-based clinical development and regulatory engagement, although certain research collaborations and clinical activities may have involved international investigators or service providers typical of the biotechnology industry.

The company’s market visibility was concentrated in North America, particularly through public market participation and clinical-stage development efforts. There is limited verified evidence of substantial operational infrastructure across Europe, Asia-Pacific, or other major global regions. Available public disclosures do not demonstrate a broad multinational commercial presence or significant international manufacturing operations.

Leadership & Governance

Arno Therapeutics was led by executives with backgrounds in biotechnology, oncology development, and pharmaceutical commercialization. Historical corporate governance materials and regulatory filings indicate that leadership focused on advancing clinical-stage oncology assets while pursuing financing and partnership opportunities necessary for continued drug development. Public information regarding the company’s current management structure and governance framework is limited, and recent verifiable updates are not consistently available.

Key historical executives identified in public records include:

• Dr. James A. Bianco – Chief Executive Officer
• Charles J. Casper – Chairman
• Glenn Mattes – Executive Chairman (historical leadership role referenced in public disclosures)

Data regarding the company’s present executive team, active board composition, and current governance status is inconclusive based on available public sources.